Guiding Bispecific Antibody Use in Non-Hodgkin Lymphoma: Integrating Evidence and Enhancing Care

This activity was originally presented at the 2024 ASHP Midyear Clinical Meeting & Exhibition.

Program Description

Bispecific antibodies (BsAbs) have an established efficacy profile in treating B-cell non-Hodgkin lymphoma (NHL). But beyond their therapeutic efficacy, BsAbs offer advantages such as fewer immune reactions when compared with CAR T-cell therapy. When utilized and incorporated into clinical practice appropriately, BsAbs have the potential to enhance safety and quality of life for patients with NHL. Each BsAb has unique pharmacological characteristics that may influence treatment decisions, including route of administration, duration of therapy, and monitoring requirements that oncology pharmacists must consider, as these differences can have a major impact on therapeutic decision-making, formulary decisions, and patients’ quality of life. This program will explore clinical strategies oncology pharmacists can implement into practice to improve safety and maintain outpatient treatment of BsAbs. Panelists will present case-based scenarios addressing common operational challenges in the use of BsAbs, discussing various pharmacist roles within the health system to improve safety and uptake of these therapies.

Target audience: Health-system pharmacists and oncology pharmacists

Type of activity: Application
Release date: December 13, 2024
Expiration date: December 13, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate clinical evidence of bispecific antibodies (BsAbs) in follicular and diffuse large B-cell lymphoma to guide evidence-based decision-making in clinical practice
• Explore clinical, operational, and pharmacological variances among BsAbs for non-Hodgkin lymphoma (NHL) to guide personalized treatment selection based on patient and disease factors
• Identify solutions to simplify care coordination for patients receiving outpatient BsAb treatment for NHL
• Employ strategies within various health-system settings to improve safe use of BsAbs in NHL

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-350-H01-P. The activity is available for CE credit through December 13, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Victoria Nachar, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Advisory board: Genmab

Brooke Adams, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Johnson & Johnson, Genmab (Advisory boards)
Speaker's bureau: Pfizer

Javier Munoz, MD, MS, MBA, has the following financial relationship with a commercial interest to disclose:
Grant/Research Support: Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, BeiGene
Consultant: Pharmacyclics/AbbVie, Bayer, Gilead/Kite, BeiGene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genentech/Roche, ADC Therapeutics, Epizyme, BeiGene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly and Company.

Medical reviewer Sarah Rockwell, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Johnson & Johnson, Bristol Myers Squibb.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

View Slides